TP53 and ovarian carcinoma: To investigate whether co-occurrence of RB1 and BRCA alterations enhances sensitivity to standard-of-care ovarian cancer drugs, nine patient-derived HGSC cell lines with confirmed pathogenic TP53 mutation and known RB1 and BRCA status were treated with cisplatin, paclitaxel, and olaparib (Supplementary Fig. S4A and S4B; Supplementary Table S17).